16-week positive results of the phase 3 RCT testing the efficacy of Ixekizumab in bDMARD-naive r-axSpA patients presented by Professor Désirée van der Heijde in #ACR18 in Chicago. Note: study not powered to compare Ixekizumab to Adalimumab